Early Switch to Mammalian Target of Rapamycin Inhibitors Is a Sustainable Treatment Approach in Renal Transplant Recipients: 7-Year Results

dc.contributor.authors	Turunc, V; Acikgoz, SB; Dheir, H;
dc.date.accessioned	2020-02-27T08:28:05Z
dc.date.available	2020-02-27T08:28:05Z
dc.date.issued	2019
dc.identifier.citation	Turunc, V; Acikgoz, SB; Dheir, H; (2019). Early Switch to Mammalian Target of Rapamycin Inhibitors Is a Sustainable Treatment Approach in Renal Transplant Recipients: 7-Year Results. TRANSPLANTATION PROCEEDINGS, 51, 1073-1070
dc.identifier.issn	0041-1345
dc.identifier.uri	https://doi.org/10.1016/j.transproceed.2019.01.098
dc.identifier.uri	https://hdl.handle.net/20.500.12619/66029
dc.description.abstract	Conclusion. Switching to m-TORi in the early posttransplant period is a safe and sustainable treatment approach.
dc.language	English
dc.publisher	ELSEVIER SCIENCE INC
dc.subject	Transplantation
dc.title	Early Switch to Mammalian Target of Rapamycin Inhibitors Is a Sustainable Treatment Approach in Renal Transplant Recipients: 7-Year Results
dc.type	Proceedings Paper
dc.identifier.volume	51
dc.identifier.startpage	1070
dc.identifier.endpage	1073
dc.contributor.department	Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü
dc.contributor.saüauthor	Dheir, Hamad
dc.relation.journal	TRANSPLANTATION PROCEEDINGS
dc.identifier.wos	WOS:000500179300013
dc.identifier.doi	10.1016/j.transproceed.2019.01.098
dc.identifier.eissn	1873-2623
dc.contributor.author	Dheir, Hamad